Search Results
Search for other papers by Yansu Wang in
Google Scholar
PubMed
Search for other papers by Yun Shen in
Google Scholar
PubMed
Search for other papers by Tingting Hu in
Google Scholar
PubMed
Search for other papers by Yufei Wang in
Google Scholar
PubMed
Search for other papers by Xiaojing Ma in
Google Scholar
PubMed
Search for other papers by Haoyong Yu in
Google Scholar
PubMed
Search for other papers by Yuqian Bao in
Google Scholar
PubMed
Introduction Non-alcoholic fatty liver disease (NAFLD) is a metabolic stress-induced liver injury that is pathologically manifested by excessive triglyceride deposition in hepatocytes. It is the most prevalent chronic liver disease worldwide
Department of Electronic Science, State Key Laboratory of Physical Chemistry of Solid Surfaces, Xiamen University, Xiamen, China
Search for other papers by Jia Li in
Google Scholar
PubMed
Search for other papers by Yan Zhao in
Google Scholar
PubMed
Search for other papers by Caoxin Huang in
Google Scholar
PubMed
Search for other papers by Zheng Chen in
Google Scholar
PubMed
Search for other papers by Xiulin Shi in
Google Scholar
PubMed
Search for other papers by Long Li in
Google Scholar
PubMed
Search for other papers by Zhong Chen in
Google Scholar
PubMed
Search for other papers by Xuejun Li in
Google Scholar
PubMed
Introduction Nonalcoholic fatty liver disease (NAFLD) has become an important public health problem because of its high prevalence with lifestyle improvements. Currently, the principal treatment for NAFLD is lifestyle modification by diet and
Zealand Pharma A/S, Søborg, Denmark
Search for other papers by Iben Rix in
Google Scholar
PubMed
Search for other papers by Marie L Johansen in
Google Scholar
PubMed
Search for other papers by Asger Lund in
Google Scholar
PubMed
Search for other papers by Malte P Suppli in
Google Scholar
PubMed
Search for other papers by Elizaveta Chabanova in
Google Scholar
PubMed
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Gerrit van Hall in
Google Scholar
PubMed
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Jens J Holst in
Google Scholar
PubMed
Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Nicolai J Wewer Albrechtsen in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Caroline Kistorp in
Google Scholar
PubMed
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Steno Diabetes Center Copenhagen, Herlev, Denmark
Search for other papers by Filip K Knop in
Google Scholar
PubMed
restoring amino acid turnover. The price for this is, however, that glucose production increases, as glucagon action on glucose production seems to be preserved in non-alcoholic fatty liver disease (NAFLD) ( 10 , 12 ). The mechanisms underlying this hepatic
Search for other papers by Jun-Xin Yan in
Google Scholar
PubMed
Search for other papers by Bin-Jing Pan in
Google Scholar
PubMed
Search for other papers by Ping-Ping Zhao in
Google Scholar
PubMed
Department of Endocrinology, The First Hospital of Lanzhou University, Lanzhou, Gansu, China
Search for other papers by Li-Ting Wang in
Google Scholar
PubMed
Department of Endocrinology, The First Hospital of Lanzhou University, Lanzhou, Gansu, China
Search for other papers by Jing-Fang Liu in
Google Scholar
PubMed
Department of Endocrinology, The First Hospital of Lanzhou University, Lanzhou, Gansu, China
Search for other papers by Song-Bo Fu in
Google Scholar
PubMed
Introduction Non-alcoholic fatty liver disease (NAFLD), which is the excessive deposition of fat (>5% of the liver weight) in liver cells without causes such as heavy drinking, hypothyroidism, or drugs, is considered a liver manifestation of
Centre for Biological Timing, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
Search for other papers by Robert Maidstone in
Google Scholar
PubMed
Diabetes, Endocrinology and Metabolism Centre, Manchester University NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, Manchester Academic Health Science Centre, Manchester, UK
Search for other papers by Martin K Rutter in
Google Scholar
PubMed
Oxford Liver Unit, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, UK
Search for other papers by Thomas Marjot in
Google Scholar
PubMed
NIHR Oxford Health Biomedical Research Centre, and NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK
Search for other papers by David W Ray in
Google Scholar
PubMed
NIHR Oxford Health Biomedical Research Centre, and NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, UK
Search for other papers by Matthew Baxter in
Google Scholar
PubMed
Fazel Y Henry L & Wymer M . Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes . Hepatology 2016 64 73 – 84 . ( https://doi.org/10.1002/hep.28431 ) 2 European Association
Search for other papers by Zhiyan Yu in
Google Scholar
PubMed
Search for other papers by Yueyue Wu in
Google Scholar
PubMed
Search for other papers by Rui Zhang in
Google Scholar
PubMed
Search for other papers by Yue Li in
Google Scholar
PubMed
Search for other papers by Shufei Zang in
Google Scholar
PubMed
Search for other papers by Jun Liu in
Google Scholar
PubMed
factor-1 and hypoalbuminemia. Non-alcoholic fatty liver disease (NAFLD) affecting multiple extrahepatic organs is considered a multi-system disease ( 2 ). Recent studies have shown that NAFLD is a high risk factor for osteoporosis ( 3 ). Several studies
Search for other papers by David Koeckerling in
Google Scholar
PubMed
Search for other papers by Jeremy W Tomlinson in
Google Scholar
PubMed
Search for other papers by Jeremy F Cobbold in
Google Scholar
PubMed
Why fight liver fat? What is NAFLD? Non-alcoholic fatty liver disease (NAFLD) is recognised as the most common aetiology of chronic liver disease, with an estimated global prevalence of 25.2%, and as a major cause of cirrhosis and
Search for other papers by Karim Gariani in
Google Scholar
PubMed
Diabetes Center, Faculty of Medicine, University of Geneva, Geneva, Switzerland
Search for other papers by François R Jornayvaz in
Google Scholar
PubMed
Introduction Nonalcoholic steatohepatitis (NASH) is part of a disease spectrum, nonalcoholic fatty liver disease (NAFLD), which ranges from simple steatosis to fibrosis and ultimately cirrhosis ( 1 , 2 , 3 , 4 ). NASH is, therefore, a
Search for other papers by Khaled Kabarra in
Google Scholar
PubMed
Search for other papers by Pegah Golabi in
Google Scholar
PubMed
Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA
Inova Medicine, Inova Health System, Falls Church, Virginia, USA
Search for other papers by Zobair M Younossi in
Google Scholar
PubMed
Introduction Nonalcoholic fatty liver disease (NAFLD) and its subtype of nonalcoholic steatohepatitis (NASH) were first described in the 1980s, coinciding with a rapid rise in epidemic of obesity ( 1 , 2 ). Increasingly, NAFLD has been
Search for other papers by Aneta Gawlik in
Google Scholar
PubMed
Search for other papers by Michael Shmoish in
Google Scholar
PubMed
Search for other papers by Michaela F Hartmann in
Google Scholar
PubMed
Search for other papers by Stefan A Wudy in
Google Scholar
PubMed
Search for other papers by Zbigniew Olczak in
Google Scholar
PubMed
Search for other papers by Katarzyna Gruszczynska in
Google Scholar
PubMed
Search for other papers by Ze’ev Hochberg in
Google Scholar
PubMed
Introduction Nonsyndromic childhood obesity is associated with nonalcoholic fatty liver disease (NAFLD), a spectrum of conditions, ranging from steatosis to nonalcoholic steatohepatitis (NASH), and various degrees of fibrosis and cirrhosis ( 1